Legend Biotech (NASDAQ:LEGN – Get Free Report) and Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.
Earnings & Valuation
This table compares Legend Biotech and Anavex Life Sciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Legend Biotech | $1.03 billion | 3.26 | -$296.80 million | ($0.80) | -22.70 |
| Anavex Life Sciences | N/A | N/A | -$46.38 million | ($0.46) | -6.41 |
Analyst Ratings
This is a summary of recent ratings for Legend Biotech and Anavex Life Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Legend Biotech | 1 | 3 | 11 | 0 | 2.67 |
| Anavex Life Sciences | 1 | 1 | 2 | 0 | 2.25 |
Legend Biotech currently has a consensus target price of $58.31, indicating a potential upside of 221.08%. Anavex Life Sciences has a consensus target price of $22.00, indicating a potential upside of 645.76%. Given Anavex Life Sciences’ higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than Legend Biotech.
Insider and Institutional Ownership
70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Legend Biotech and Anavex Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Legend Biotech | -28.86% | -21.93% | -13.21% |
| Anavex Life Sciences | N/A | -38.76% | -35.01% |
Risk and Volatility
Legend Biotech has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.
Summary
Anavex Life Sciences beats Legend Biotech on 7 of the 13 factors compared between the two stocks.
About Legend Biotech
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
About Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
